Prudential Financial Inc. Cuts Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Prudential Financial Inc. reduced its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.6% during the fourth quarter, HoldingsChannel.com reports. The fund owned 38,694 shares of the company’s stock after selling 630 shares during the quarter. Prudential Financial Inc.’s holdings in Amphastar Pharmaceuticals were worth $1,437,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. raised its stake in shares of Amphastar Pharmaceuticals by 53.4% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock valued at $56,000 after acquiring an additional 398 shares during the period. Point72 DIFC Ltd raised its position in shares of Amphastar Pharmaceuticals by 85.9% in the 3rd quarter. Point72 DIFC Ltd now owns 3,954 shares of the company’s stock worth $192,000 after acquiring an additional 1,827 shares in the last quarter. Weiss Asset Management LP purchased a new stake in shares of Amphastar Pharmaceuticals during the third quarter valued at about $4,967,000. Wellington Management Group LLP purchased a new stake in Amphastar Pharmaceuticals during the third quarter valued at approximately $957,000. Finally, XTX Topco Ltd purchased a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at approximately $674,000. 65.09% of the stock is owned by institutional investors.

Amphastar Pharmaceuticals Stock Down 2.3 %

Amphastar Pharmaceuticals stock opened at $26.61 on Friday. The stock has a market cap of $1.27 billion, a PE ratio of 8.87, a P/E/G ratio of 2.19 and a beta of 0.79. Amphastar Pharmaceuticals, Inc. has a 1-year low of $25.89 and a 1-year high of $53.96. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The stock’s fifty day moving average is $30.24 and its two-hundred day moving average is $39.25.

Insider Activity

In related news, CFO William J. Peters sold 4,231 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares in the company, valued at $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 27.10% of the company’s stock.

Analysts Set New Price Targets

Separately, Piper Sandler lowered their target price on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research note on Friday, March 21st.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.